Download PDF
Nervenheilkunde 2021; 40(01/02): 35-42
DOI: 10.1055/a-1301-3135
Schwerpunkt

Endocannabinoidsystem und Stress

Mehr als nur ein „high“?Endocannabinoid system and stressMore than just a „high“?
Jennifer Spohrs∗
1   Klinik für Kinder- und Jugendpsychiatrie und Psychotherapie III, Universitätsklinikum Ulm
,
Martin Ulrich∗
2   Klinik für Psychiatrie und Psychotherapie III, Universitätsklinikum Ulm
,
Birgit Abler∗
2   Klinik für Psychiatrie und Psychotherapie III, Universitätsklinikum Ulm
› Author Affiliations
› Further Information
    Permissions and Reprints

ZUSAMMENFASSUNG

Das wissenschaftliche Interesse am Endocannabinoidsystem hat in den vergangenen Jahren aufgrund der zunehmenden Legalisierung von medizinischem Cannabis und seiner anxiolytischen Wirkung eine breite Basis von Tierexperimenten und erste translationale Studien zu biologischen, genetischen und neurobiologischen Befunden generiert. Besonders die modulatorische Rolle von Endocannabinoiden im Rahmen von Stress- und Angsterkrankungen steht im Vordergrund und weist auf mögliche Interventionspunkte hin, um vorhandene Therapien zu verbessern. Es fehlen jedoch weiterhin Erkenntnisse und Studien zur Wirkweise am Menschen, um die Implementierung dieser therapeutischen Anknüpfungspunkte umzusetzen. Die folgende Arbeit stellt eine Übersicht mit Schwerpunkt auf der Grundlagenforschung zum Endocannabinoidsystem im Rahmen von stressbezogenen Prozessen dar.

ABSTRACT

The interest in the endocannabinoid system has, due to the increasing legalization of medical cannabis and its anxiolytic capacities, generated many rodent and first human studies investigating the biological, genetic and neurobiological basis. Especially the modulatory role in stress- and anxiety disorders has been of interest and points towards possible nodes for interventions to enhance current therapies. However, more findings and studies in humans are necessary to implement these therapeutic links. The present work gives an overview with an emphasis on basic research on the endocannabinoid system in stress-related processes.

Schlüsselwörter

Endocannabinoidsystem - Stress - Angsterkrankung - Anandamid - 2-AG

Key words

Endocannabinoid system - stress - anxiety disorder - anandamide - 2-AG


Publication History

Article published online:
04 February 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Greenberg MS, Tanev K, Marin MF. et al Stress, PTSD, and dementia. Alzheimers Dement 2014; 10 (03) S155-165
    CrossrefPubMedGoogle Scholar
  • 2 Park C, Rosenblat JD, Brietzke E. et al Stress, epigenetics and depression: A systematic review. Neurosci Biobehav Rev 2019; 102: 139-152
    CrossrefPubMedGoogle Scholar
  • 3 Reiche EM, Nunes SO, Morimoto HK. Stress, depression, the immune system, and cancer. The Lancet Oncology 2004; 5 (10) 617-625
    CrossrefPubMedGoogle Scholar
  • 4 Howes OD, McCutcheon R, Owen MJ. et al The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia. Biol Psychiatry 2017; 81 (01/02) 9-20
    CrossrefPubMedGoogle Scholar
  • 5 Kivimaki M, Steptoe A. Effects of stress on the development and progression of cardiovascular disease. Nat Rev Cardiol 2018; 15 (04) 215-229
    CrossrefPubMedGoogle Scholar
  • 6 Godoy LD, Rossignoli MT, Delfino-Pereira P. et al A Comprehensive Overview on Stress Neurobiology: Basic Concepts and Clinical Implications. Front Behav Neurosci 2018; 12: 127
    CrossrefPubMedGoogle Scholar
  • 7 Jie F, Yin G, Yang W. et al Stress in Regulation of GABA Amygdala System and Relevance to Neuropsychiatric Diseases. Front Neurosci 2018; 12: 562
    CrossrefPubMedGoogle Scholar
  • 8 Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3 (09) 771-784
    CrossrefPubMedGoogle Scholar
  • 9 Mechoulam R, Gaoni Y. The absolute configuration of delta-1-tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Lett 1967; 12: 1109-1111
    CrossrefPubMedGoogle Scholar
  • 10 Mechoulam R, Braun P, Gaoni Y. A stereospecific synthesis of (-)-delta 1- and (-)-delta 1(6)-tetrahydrocannabinols. J Am Chem Soc 1967; 89 (17) 4552-4554
    CrossrefPubMedGoogle Scholar
  • 11 Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74 (02) 129-180
    CrossrefPubMedGoogle Scholar
  • 12 Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365 6441 61-65
    CrossrefPubMedGoogle Scholar
  • 13 Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006; 66 (02) 234-246
    CrossrefPubMedGoogle Scholar
  • 14 McAllister SD, Glass M. CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids. Prostaglandins, leukotrienes, and essential fatty acids 2002; 66 2–3 161-171
    CrossrefPubMedGoogle Scholar
  • 15 Coccaro EF, Hill MN, Robinson L. et al Circulating endocannabinoids and affect regulation in human subjects. Psychoneuroendocrinology 2018; 92: 66-71
    CrossrefPubMedGoogle Scholar
  • 16 De Marchi N, De Petrocellis L, Orlando P. et al Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis 2003; 2: 5
    CrossrefPubMedGoogle Scholar
  • 17 Hill MN, Miller GE, Carrier EJ. et al Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology 2009; 34 (08) 1257-1262
    CrossrefPubMedGoogle Scholar
  • 18 Koethe D, Hoyer C, Leweke FM. The endocannabinoid system as a target for modelling psychosis. Psychopharmacology (Berl) 2009; 206 (04) 551-561
    CrossrefPubMedGoogle Scholar
  • 19 Laezza C, Pagano C, Navarra G. et al The Endocannabinoid System: A Target for Cancer Treatment. Int J Mol Sci 2020; 21: 3
    CrossrefPubMedGoogle Scholar
  • 20 Li GL, Winter H, Arends R. et al Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects. Br J Clin Pharmacol 2012; 73 (05) 706-716
    CrossrefPubMedGoogle Scholar
  • 21 Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol 2013; 64: 21-47
    CrossrefPubMedGoogle Scholar
  • 22 Seeman P. Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. Transl Psychiatry 2016; 6 (10) e920
    CrossrefPubMedGoogle Scholar
  • 23 Wirz L, Reuter M, Felten A. et al An endocannabinoid receptor polymorphism modulates affective processing under stress. Soc Cogn Affect Neurosci 2018; 13 (11) 1177-1189
    PubMedGoogle Scholar
  • 24 Woodhams SG, Chapman V, Finn D. et al The cannabinoid system and pain. Neuropharmacology 2017; 124: 105-120
    CrossrefPubMedGoogle Scholar
  • 25 Sarvet AL, Wall MM, Keyes KM. et al Self-medication of mood and anxiety disorders with marijuana: Higher in states with medical marijuana laws. Drug Alcohol Depend 2018; 186: 10-15
    CrossrefPubMedGoogle Scholar
  • 26 Cascini F, Aiello C, Di Tanna G. Increasing delta-9-tetrahydrocannabinol (Delta-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev 2012; 5 (01/02) 32-40
    CrossrefPubMedGoogle Scholar
  • 27 Curran HV, Freeman TP, Mokrysz C. et al Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci 2016; 17 (05) 293-306
    CrossrefPubMedGoogle Scholar
  • 28 ElSohly MA, Mehmedic Z, Foster S. et al Changes in Cannabis Potency Over the Last 2 Decades 1995– 2014 Analysis of Current Data in the United States. Biol Psychiatry 2016; 79 (07) 613-619
    CrossrefPubMedGoogle Scholar
  • 29 Englund A, Freeman TP, Murray RM. et al Can we make cannabis safer?. Lancet Psychiatry 2017; 4 (08) 643-648
    CrossrefPubMedGoogle Scholar
  • 30 Morgan CJ, Gardener C, Schafer G. et al Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol Med 2012; 42 (02) 391-400
    CrossrefPubMedGoogle Scholar
  • 31 Andrade AK, Renda B, Murray JE. Cannabinoids, interoception, and anxiety. Pharmacology, biochemistry, and behavior 2019; 180: 60-73
    CrossrefPubMedGoogle Scholar
  • 32 Papagianni EP, Stevenson CW. Cannabinoid Regulation of Fear and Anxiety: an Update. Curr Psychiatry Rep 2019; 21 (06) 38
    CrossrefPubMedGoogle Scholar
  • 33 Ruehle S, Rey AA, Remmers F. et al The endocannabinoid system in anxiety, fear memory and habituation. J Psychopharmacol (Oxf) 2012; 26 (01/02) 23-39
    CrossrefPubMedGoogle Scholar
  • 34 Viveros MP, Marco EM, File SE. Endocannabinoid system and stress and anxiety responses. Pharmacology, biochemistry, and behavior 2005; 81 (02) 331-342
    CrossrefPubMedGoogle Scholar
  • 35 Blessing EM, Steenkamp MM, Manzanares J. et al Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics 2015; 12 (04) 825-836
    CrossrefPubMedGoogle Scholar
  • 36 Patel S, Hillard CJ. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. The Journal of pharmacology and experimental therapeutics 2006; 318 (01/02) 304-311
    CrossrefPubMedGoogle Scholar
  • 37 Zuardi AW, Finkelfarb E, Bueno OF. et al Characteristics of the stimulus produced by the mixture of cannabidiol with delta 9-tetrahydrocannabinol. Arch Int Pharmacodyn Ther 1981; 249 (01/02) 137-146
    PubMedGoogle Scholar
  • 38 Bloomfield MAP, Hindocha C, Green SF. et al The neuropsychopharmacology of cannabis: A review of human imaging studies. Pharmacol Ther 2019; 195: 132-161
    CrossrefPubMedGoogle Scholar
  • 39 Freeman AM, Petrilli K, Lees R. et al How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review. Neurosci Biobehav Rev 2019; 107: 696-712
    CrossrefPubMedGoogle Scholar
  • 40 Fusar-Poli P, Crippa JA, Bhattacharyya S. et al Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 2009; 66 (01/02) 95-105
    CrossrefPubMedGoogle Scholar
  • 41 Karniol IG, Shirakawa I, Kasinski N. et al Cannabidiol interferes with the effects of delta 9 – tetrahydrocannabinol in man. Eur J Pharmacol 1974; 28 (01/02) 172-177
    CrossrefPubMedGoogle Scholar
  • 42 Campos AC, Ortega Z, Palazuelos J. et al The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. The international journal of neuropsychopharmacology 2013; 16 (06) 1407-1419
    CrossrefPubMedGoogle Scholar
  • 43 Lee JLC, Bertoglio LJ, Guimaraes FS. et al Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders. Br J Pharmacol 2017; 174 (19) 3242-3256
    CrossrefPubMedGoogle Scholar
  • 44 Yarkoni T, Poldrack RA, Van Essen DC. et al Cognitive neuroscience 2.0: building a cumulative science of human brain function. Trends Cogn Sci 2010; 14 (11) 489-496
    CrossrefPubMedGoogle Scholar
  • 45 Bisogno T, Maccarrone M. Latest advances in the discovery of fatty acid amide hydrolase inhibitors. Expert Opin Drug Discov 2013; 8 (05) 509-522
    CrossrefPubMedGoogle Scholar
  • 46 De Petrocellis L, Ligresti A, Moriello AS. et al Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 2011; 163 (07) 1479-1494
    CrossrefPubMedGoogle Scholar
  • 47 Elmes MW, Kaczocha M, Berger WT. et al Fatty acid-binding proteins (FABPs) are intracellular carriers for Delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD). The Journal of biological chemistry 2015; 290 (14) 8711-8721
    CrossrefPubMedGoogle Scholar
  • 48 Chessick CA, Allen MH, Thase M. et al Azapirones for generalized anxiety disorder. The Cochrane database of systematic reviews. 2006 3 CD006115
    PubMedGoogle Scholar
  • 49 Lutz B, Marsicano G, Maldonado R. et al The endocannabinoid system in guarding against fear, anxiety and stress. Nat Rev Neurosci 2015; 16 (12) 705-718
    CrossrefPubMedGoogle Scholar
  • 50 Hillard CJ. Circulating endocannabinoids: From whence do they come and where are they going?. Neuropsychopharmacology 2018; 43 (01/02) 155-172
    CrossrefPubMedGoogle Scholar
  • 51 Gil-Ordonez A, Martin-Fontecha M, Ortega-Gutierrez S. et al Monoacylglycerol lipase (MAGL) as a promising therapeutic target. Biochem Pharmacol 2018; 157: 18-32
    CrossrefPubMedGoogle Scholar
  • 52 Gunduz-Cinar O, Hill MN, McEwen BS. et al Amygdala FAAH and anandamide: mediating protection and recovery from stress. Trends Pharmacol Sci 2013; 34 (11) 637-644
    CrossrefPubMedGoogle Scholar
  • 53 Hill MN, Kumar SA, Filipski SB. et al Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure. Mol Psychiatry 2013; 18 (10) 1125-1135
    CrossrefPubMedGoogle Scholar
  • 54 Mayo LM, Asratian A, Linde J. et al Elevated Anandamide, Enhanced Recall of Fear Extinction, and Attenuated Stress Responses Following Inhibition of Fatty Acid Amide Hydrolase: A Randomized, Controlled Experimental Medicine Trial. Biol Psychiatry 2020; 87 (06) 538-547
    CrossrefPubMedGoogle Scholar
  • 55 Rabinak CA, Phan KL. Cannabinoid modulation of fear extinction brain circuits: a novel target to advance anxiety treatment. Curr Pharm Des 2014; 20 (13) 2212-2217
    CrossrefPubMedGoogle Scholar
  • 56 Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997; 77 (02) 299-318
    CrossrefPubMedGoogle Scholar
  • 57 Westlake TM, Howlett AC, Bonner TI. et al Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer’s brains. Neuroscience 1994; 63 (03) 637-652
    CrossrefPubMedGoogle Scholar
  • 58 Worley NB, Hill MN, Christianson JP. Prefrontal endocannabinoids, stress controllability and resilience: A hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 2018; 85: 180-188
    CrossrefPubMedGoogle Scholar
  • 59 Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science 2002; 296 5568 678-682
    CrossrefPubMedGoogle Scholar
  • 60 Nyilas R, Dudok B, Urban GM. et al Enzymatic machinery for endocannabinoid biosynthesis associated with calcium stores in glutamatergic axon terminals. The Journal of neuroscience : the official journal of the Society for Neuroscience 2008; 28 (05) 1058-1063
    CrossrefPubMedGoogle Scholar
  • 61 Howlett AC. The cannabinoid receptors. Prostaglandins Other Lipid Mediat 2002; 68 (69) 619-631
    CrossrefPubMedGoogle Scholar
  • 62 Ahn K, McKinney MK, Cravatt BF. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 2008; 108 (05) 1687-1707
    CrossrefPubMedGoogle Scholar
  • 63 Ligresti A, De Petrocellis L, Di Marzo V. From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology. Physiol Rev 2016; 96 (04) 1593-1659
    CrossrefPubMedGoogle Scholar
  • 64 Lee SH, Ledri M, Toth B. et al Multiple Forms of Endocannabinoid and Endovanilloid Signaling Regulate the Tonic Control of GABA Release. The Journal of neuroscience : the official journal of the Society for Neuroscience 2015; 35 (27) 10039-10057
    CrossrefPubMedGoogle Scholar
  • 65 Hillard CJ. Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostaglandins Other Lipid Mediat 2000; 61 1–2 3-18
    CrossrefPubMedGoogle Scholar
  • 66 Kim J, Alger BE. Reduction in endocannabinoid tone is a homeostatic mechanism for specific inhibitory synapses. Nat Neurosci 2010; 13 (05) 592-600
    CrossrefPubMedGoogle Scholar
  • 67 Morena M, Patel S, Bains JS. et al Neurobiological Interactions Between Stress and the Endocannabinoid System. Neuropsychopharmacology 2016; 41 (01/02) 80-102
    CrossrefPubMedGoogle Scholar
  • 68 Sigel E, Baur R, Racz I. et al The major central endocannabinoid directly acts at GABA(A) receptors. Proc Natl Acad Sci U S A 2011; 108 (44) 18150-18155
    CrossrefPubMedGoogle Scholar
  • 69 Castillo PE, Younts TJ, Chavez AE. et al Endocannabinoid signaling and synaptic function. Neuron 2012; 76 (01/02) 70-81
    CrossrefPubMedGoogle Scholar
  • 70 Gunduz-Cinar O. The endocannabinoid system in the amygdala and modulation of fear. Prog Neuropsychopharmacol Biol Psychiatry 2020; 105: 110116
    CrossrefPubMedGoogle Scholar
  • 71 Duval ER, Javanbakht A, Liberzon I. Neural circuits in anxiety and stress disorders: a focused review. Ther Clin Risk Manag 2015; 11: 115-126
    PubMedGoogle Scholar
  • 72 Walker EF, Diforio D. Schizophrenia: a neural diathesis-stress model. Psychol Rev 1997; 104 (04) 667-685
    CrossrefPubMedGoogle Scholar
  • 73 Zajkowska ZE, Englund A, Zunszain PA. Towards a personalized treatment in depression: endocannabinoids, inflammation and stress response. Pharmacogenomics 2014; 15 (05) 687-698
    CrossrefPubMedGoogle Scholar
  • 74 Musazzi L, Tornese P, Sala N. et al Acute or Chronic? A Stressful Question. Trends Neurosci 2017; 40 (09) 525-535
    CrossrefPubMedGoogle Scholar
  • 75 Stephens MA, Wand G. Stress and the HPA axis: role of glucocorticoids in alcohol dependence. Alcohol Res 2012; 34 (04) 468-483
    PubMedGoogle Scholar
  • 76 Etkin A, Egner T, Kalisch R. Emotional processing in anterior cingulate and medial prefrontal cortex. Trends Cogn Sci 2011; 15 (02) 85-93
    CrossrefPubMedGoogle Scholar
  • 77 McEwen BS, Bowles NP, Gray JD. et al Mechanisms of stress in the brain. Nat Neurosci 2015; 18 (10) 1353-1363
    CrossrefPubMedGoogle Scholar
  • 78 Gray JM, Vecchiarelli HA, Morena M. et al Corticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety. Journal of neuroscience 2015; 35 (09) 3879-3892
    CrossrefPubMedGoogle Scholar
  • 79 Hill MN, McLaughlin RJ, Bingham B. et al Endogenous cannabinoid signaling is essential for stress adaptation. Proc Natl Acad Sci U S A 2010; 107 (20) 9406-9411
    CrossrefPubMedGoogle Scholar
  • 80 Morena M, Campolongo P. The endocannabinoid system: an emotional buffer in the modulation of memory function. Neurobiol Learn Mem 2014; 112: 30-43
    CrossrefPubMedGoogle Scholar
  • 81 Haller J, Barna I, Barsvari B. et al Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats. Psychopharmacology (Berl) 2009; 204 (04) 607-616
    CrossrefPubMedGoogle Scholar
  • 82 Patel S, Cravatt BF, Hillard CJ. Synergistic interactions between cannabinoids and environmental stress in the activation of the central amygdala. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2005; 30 (03) 497-507
    CrossrefPubMedGoogle Scholar
  • 83 Mayo LM, Asratian A, Linde J. et al Protective effects of elevated anandamide on stress and fear-related behaviors: translational evidence from humans and mice. Mol Psychiatry 2018; 25: 993-1005
    CrossrefPubMedGoogle Scholar
  • 84 McLaughlin RJ, Hill MN, Bambico FR. et al Prefrontal cortical anandamide signaling coordinates coping responses to stress through a serotonergic pathway. European neuropsychopharmacology 2012; 22 (09) 664-671
    CrossrefPubMedGoogle Scholar
  • 85 Hayes JP, Hayes SM, Mikedis AM. Quantitative meta-analysis of neural activity in posttraumatic stress disorder. Biol Mood Anxiety Disord 2012; 2: 9
    CrossrefPubMedGoogle Scholar
  • 86 Sumislawski JJ, Ramikie TS, Patel S. Reversible gating of endocannabinoid plasticity in the amygdala by chronic stress: a potential role for monoacylglycerol lipase inhibition in the prevention of stress-induced behavioral adaptation. Neuropsychopharmacology 2011; 36 (13) 2750-2761
    CrossrefPubMedGoogle Scholar
  • 87 Refojo D, Schweizer M, Kuehne C. et al Glutamatergic and dopaminergic neurons mediate anxiogenic and anxiolytic effects of CRHR1. Science 2011; 333 6051 1903-1907
    CrossrefPubMedGoogle Scholar
  • 88 Dlugos A, Childs E, Stuhr KL. et al Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans. Neuropsychopharmacology 2012; 37 (11) 2416-2427
    CrossrefPubMedGoogle Scholar
  • 89 Egmond NV, Straub VM, der Stelt MV. Targeting Endocannabinoid Signaling: FAAH and MAG Lipase Inhibitors. Annu Rev Pharmacol Toxicol 2021; 61: 1
    CrossrefPubMedGoogle Scholar
  • 90 Navarrete F, Garcia-Gutierrez MS, Jurado-Barba R. et al Endocannabinoid System Components as Potential Biomarkers in Psychiatry. Front Psychiatry 2020; 11: 315
    CrossrefPubMedGoogle Scholar